Rhythm Pharmaceuticals (RYTM) Revenue & Revenue Breakdown
Rhythm Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$130.13M
Latest Revenue (Q)
$41.83M
Main Segment (Y)
Product
Main Geography (Y)
UNITED STATES
Rhythm Pharmaceuticals Revenue by Period
Rhythm Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $130.13M | 68.06% |
| 2023-12-31 | $77.43M | 227.56% |
| 2022-12-31 | $23.64M | 649.46% |
| 2021-12-31 | $3.15M | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | 100.00% |
| 2012-12-31 | - | - |
Rhythm Pharmaceuticals generated $130.13M in revenue during NA 2024, up 68.06% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Rhythm Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-12-31 | $41.83M | 25.80% |
| 2024-09-30 | $33.25M | 14.35% |
| 2024-06-30 | $29.08M | 11.98% |
| 2024-03-31 | $25.97M | 7.15% |
| 2023-12-31 | $24.23M | 7.69% |
| 2023-09-30 | $22.50M | 17.08% |
| 2023-06-30 | $19.22M | 67.59% |
| 2023-03-31 | $11.47M | 30.48% |
| 2022-12-31 | $8.79M | 105.18% |
| 2022-09-30 | $4.28M | -52.75% |
| 2022-06-30 | $9.07M | 505.21% |
| 2022-03-31 | $1.50M | -17.56% |
| 2021-12-31 | $1.82M | 76.75% |
| 2021-09-30 | $1.03M | 275.18% |
| 2021-06-30 | $274.00K | 682.86% |
| 2021-03-31 | $35.00K | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | - |
Rhythm Pharmaceuticals generated $41.83M in revenue during Q4 2024, up 25.80% compared to the previous quarter, and up 185.88% compared to the same period a year ago.
Rhythm Pharmaceuticals Revenue Breakdown
Rhythm Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|
| Product | $130.13M | $77.43M | - |
| License | - | - | - |
| License revenue | - | - | $6.75M |
| Product revenue | - | - | $16.88M |
Rhythm Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: Product (100.00%).
Quarterly Revenue by Product
| Product/Service | Mar 25 | Dec 24 | Mar 24 | Jun 23 | Dec 22 | Sep 22 | Jun 22 |
|---|---|---|---|---|---|---|---|
| License | $-5.01M | - | - | - | - | - | - |
| Product | $37.72M | $104.16M | $25.97M | - | - | - | - |
| Product revenue | - | - | - | $19.22M | $8.79M | $4.28M | $2.31M |
| License revenue | - | - | - | - | - | - | $6.75M |
Rhythm Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 25: Product (115.33%), and License (-15.33%).
Rhythm Pharmaceuticals Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 |
|---|---|---|
| Non-US | $34.02M | - |
| UNITED STATES | $96.11M | $62.42M |
| Other Countries | - | $8.93M |
| GERMANY | - | $6.08M |
Rhythm Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (73.86%), and Non-US (26.14%).
Quarterly Revenue by Country
| Country | Mar 25 | Dec 24 | Sep 24 |
|---|---|---|---|
| Non-US | $13.35M | - | - |
| UNITED STATES | - | $72.81M | $23.30M |
| Other Countries | - | - | $6.33M |
| GERMANY | - | - | $3.62M |
Rhythm Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Mar 25: Non-US (100.00%).
Rhythm Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals | $423.24M | $137.78M |
| ARVN | Arvinas | $263.40M | $188.80M |
| RYTM | Rhythm Pharmaceuticals | $130.13M | $41.83M |
| ACLX | Arcellx | $107.94M | $15.27M |
| STOK | Stoke Therapeutics | $36.55M | $22.61M |
| MGTX | MeiraGTx | $33.28M | - |
| QURE | uniQure | $27.12M | $5.22M |
| SNDX | Syndax Pharmaceuticals | $23.68M | $20.04M |
| RNA | Avidity Biosciences | $10.90M | $2.97M |
| RLAY | Relay Therapeutics | $10.01M | $7.68M |
| CGEM | Cullinan Oncology | - | - |
| AKRO | Akero Therapeutics | - | - |
| SLDB | Solid Biosciences | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| PTGX | Protagonist Therapeutics | - | $170.64M |
| VTYX | Ventyx Biosciences | - | - |
| NUVL | Nuvalent | - | - |
| RCKT | Rocket Pharmaceuticals | - | - |
| VRDN | Viridian Therapeutics | - | $72.00K |
| RVMD | Revolution Medicines | - | - |
| INZY | Inozyme Pharma | - | - |
| PLRX | Pliant Therapeutics | - | - |